Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Sattva S Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD MMSc, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric Van Den Neste, MD, Umar Farooq, MD, Lynn Navale, MS, Venita DePuy, PhD, Jenny J. Kim, MD MS, Christian Gisselbrecht, MD

Blood (2019) 134 (Supplement_1): 4095.

https://doi.org/10.1182/blood-2019-125792

Published: 2019

Journal Articles

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Jordon Jaggers, Heidi D. Klepin, MD, Tanya M. Wildes, MD, Rebecca L. Olin, MD, Andrew S. Artz, MD, Sarah A Wall, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5819.

https://doi.org/10.1182/blood-2019-131504

Published: 2019

Journal Articles

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Adeela Mushtaq, MD, Hamza Hassan, MD MBBS, Razwana Khanam, MD, Ahmad Iftikhar, MD, Midhat Lakhani, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Seemal Iftikhar, MD, Aneeqa A Zafar, MD, Irbaz Riaz, MDMMSc, M Hasib Sidiqi, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5556.

https://doi.org/10.1182/blood-2019-125148

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Steven Devine, Stephan Mielke, MD, Eduardo Olavarria, Bert Tuk, Kees Meewisse, Andrew Sandler, MD, Denis-Claude Roy, MD

Blood (2018) 132 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2018-99-118857

Published: 2018

Journal Articles

The Impact of RVD or VCD Induction on Response 3 Months after First Line Autologous Transplant in Multiple Myeloma. a Single-Center Retrospective Analysis

Magnus Moksnes, MD, Fredrik H. Schjesvold, MD PhD

Blood (2018) 132 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2018-99-113270

Published: 2018

Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Blood (2018) 132 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2018-99-111369

Published: 2018

Journal Articles

High-Density Data Mining to Identify Unique Toxicities of Adolescent/Young Adult Cancer Treatment: A Report from the Children's Oncology Group

Mayur Sarangdhar, PhD, Susan L. Whiteway, MD, Jessica L. Heath, MD, Elizabeth A. Raetz, MD, Emily Hibbits, PhD, Meenakshi Devidas, PhD, David R. Freyer, DO, John Peter Perentesis, MD

Blood (2017) 130 (Supplement 1): 2562.

https://doi.org/10.1182/blood.V130.Suppl_1.2562.2562

Published: 2017

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Blood (2017) 130 (Supplement 1): 1750.

https://doi.org/10.1182/blood.V130.Suppl_1.1750.1750

Published: 2017

Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD

Blood (2016) 128 (22): 3095.

https://doi.org/10.1182/blood.V128.22.3095.3095

Published: 2016

Journal Articles

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Blood (2016) 127 (24): 2955–2962.

https://doi.org/10.1182/blood-2016-01-631200

Published: 2016

Includes: Supplemental data

Journal Articles

Sickle Cell Disease Measures in the Phenx Toolkit

Kathryn L. Hassell, MD, James R. Eckman, MD, Elizabeth S Klings, MD, Robert J. Adams, MD MS, Julie A. Panepinto, MD MSPH, Tracey Grant, MS, Wayne Huggins, PhD, Deborah R. Maiese, MPA, Ellen M. Werner, PhD, Erin M. Ramos, PhD MPH, Carol M. Hamilton, PhD

Blood (2015) 126 (23): 281.

https://doi.org/10.1182/blood.V126.23.281.281

Published: 2015

Journal Articles

Deferiprone Pharmacokinetics with and without Iron Overload and in Special Patient Populations

Michael Spino, PharmD, John Connelly, PhD, Yu-Chung Tsang, PhD, Caroline Fradette, PhD, Fernando Tricta, MD

Blood (2015) 126 (23): 3365.

https://doi.org/10.1182/blood.V126.23.3365.3365

Published: 2015

Journal Articles

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Peter Hillmen, MB, ChB, PhD, Graeme Fraser, MDFRCPC, Jeffrey Jones, MD MPH, Simon Rule, MD, Susan O'Brien, MD, Marie Sarah Dilhuydy, MD, Ulrich Jaeger, MD, Sebastian Grosicki, MD PhD, Florence Cymbalista, MD PhD, Steven Sun, PhD, Joi Ninomoto, PharmD, Michelle Mahler, MD, Mei Cheng, PhD, Joris Diels, Fong Clow, ScD, Mariya Salman, PhD, Danelle F. James, MD MAS, Angela Howes, PhD, Asher Chanan-Khan, MD

Blood (2015) 126 (23): 2944.

https://doi.org/10.1182/blood.V126.23.2944.2944

Published: 2015

Journal Articles

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Meletios A. Dimopoulos, MD, Robert Z. Orlowski, M.D., Ph.D, Thierry Facon, MD, Pieter Sonneveld, MD, Ph.D, Kenneth C. Anderson, MD, Meral Beksac, MD, Lotfi Benboubker, MD, Huw Roddie, MBChB, Ph.D, Anna Potamianou, MD, Catherine Couturier, PharmD, Huaibao Feng, Ph.D, Ozlem Ataman, MD, Ph.D, Helgi van de Velde, Paul G. Richardson, MD

Blood (2013) 122 (21): 3177.

https://doi.org/10.1182/blood.V122.21.3177.3177

Published: 2013

Journal Articles

Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies

Michinori Ogura, MD, PhD, Franck Morschhauser, MD, PhD, Kensei Tobinai, MD, PhD, Guillaume Cartron, MD, PhD, Kiyohiko Hatake, MD, PhD, Michael K. Wenger, MD, Joe Birkett, PhD, Naoko Oya, Kiyomi Nishima, Gilles Salles, MD, PhD

Blood (2010) 116 (21): 4921.

https://doi.org/10.1182/blood.V116.21.4921.4921

Published: 2010

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

NARROW

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

The Impact of RVD or VCD Induction on Response 3 Months after First Line Autologous Transplant in Multiple Myeloma. a Single-Center Retrospective Analysis

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

High-Density Data Mining to Identify Unique Toxicities of Adolescent/Young Adult Cancer Treatment: A Report from the Children's Oncology Group

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Sickle Cell Disease Measures in the Phenx Toolkit

Deferiprone Pharmacokinetics with and without Iron Overload and in Special Patient Populations

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only